ClinicalTrials.gg
CompletedNCT04225156ADVANCE+Updated Mar 16, 2026

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

A Phase 3 interventional study of efgartigimod in Primary Immune Thrombocytopenia, sponsored by argenx. Completed at 87 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey — 6 open to participants now, 10 under way, 7 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Turkey.

Enrollment
13th of 18
101 · median 144
Started
2020
with 2 others
Phase 3
13 of 19
4 open now
Registered
5th of 19
by date
Lead sponsor
4 of 19
argenx

Among the 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 3, and was the 5th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey, or all of them as a file.
02

Study summary

This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.

03

Conditions studied

  • Primary Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the requirements of the trial, to provide written (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
  2. Patients enrolled in the ARGX-113-1801 trial who completed the 24-weeks trial period.
  3. Women of must have a negative urine pregnancy test at baseline before trial medication (infusion) can be administered.
  4. Women of childbearing potential should use a highly effective or acceptable method of during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month (as listed in the protocol)

6. Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).

7. Patient has completed a 52-week treatment period.

Exclusion criteria

Exclusion criteria:

  1. Introduction or continuation of non-permitted medications during the ARGX-113-1801 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins or live/).
  2. Pregnant or lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing.
  3. Patients with known medical history of to any of the ingredients of efgartigimod.
  4. Use of any other drug or participation in any other investigational trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    efgartigimod

    patients receiving efgartigimod

    Biological: efgartigimod

Interventions

  • Biologicalefgartigimod

    Intravenous infusion of efgartigimod

    Also known as: ARGX-113

06

What researchers measure

Primary outcomes

  1. Frequency and severity of Adverse Events

    Time frame: Up to 60 weeks

  2. Frequency and severity of vital signs

    Time frame: Up to 60 weeks

  3. Frequency and severity of laboratory assessments

    Time frame: Up to 60 weeks

Secondary outcomes

  1. Extent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L.

    Time frame: Over the 52 weeks of treatment

  2. Percentage of patients with overall platelet count response defined as achieving a platelet count of ≥50×10^9/L on at least 4 occasions at any time during the 52-week treatment period.

    Time frame: Over the 52 weeks of treatment

  3. Mean change from baseline in platelet count at each visit.

    Time frame: Up to 60 weeks, at each visit

  4. For patients rolling-over from the ARGX-113-1801 trial with a platelet count of <30×10^9/L: time to response is defined as the time to achieve 2 consecutive platelet counts of ≥50×10^9/L

    Time frame: Up to 60 weeks, at each visit

  5. The percentage of weeks in the trial with platelet counts of ≥30×109/L and at least 20×10E9/L above baseline.

    Time frame: Over the 52 weeks of treatment

  6. In patients with baseline platelet count of <15×10E9/L in the current trial (ARGX-113-1803), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and at least 20×10E9/L above baseline.

    Time frame: Over the 52 weeks of treatment

  7. In patients with first exposure to efgartigimod: proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of at least 50×10^9/L for at least 4 of the 6 visits between week 19 and 24 of the trial.

    Time frame: Up to 5 weeks, between visit 19 and 24 of the trial

  8. In patients with first exposure to efgartigimod: proportion of patients in the overall population achieving platelet counts of at least 50x10^9/L for at least 6 of the 8 visits between week 17 and 24 of the trial.

    Time frame: Up to 7 weeks, between visit 17 and 24 of the trial

  9. Rate of receipt of rescue therapy (rescue per patient per month).

    Time frame: Up to 60 weeks, at each visit

  10. Reduction in concurrent ITP therapy.

    Time frame: Up to 60 weeks, at each visit

  11. Incidence and severity of the WHO-classified bleeding events.

    Time frame: Up to 60 weeks, at each visit

  12. Change from baseline in Patient reported Outcomes (FACIT-Fatigue) at planned visits.

    Time frame: Up to 52 weeks

  13. Change from baseline in Patient reported Outcomes (Fact-Th6) at planned visits.

    Time frame: Up to 52 weeks

  14. Change from baseline in Quality of Life (SF-36) at planned visits.

    Time frame: Up to 52 weeks

  15. Incidence of anti-drug antibodies (ADA) to efgartigimod.

    Time frame: Up to 216 weeks

  16. Pharmacokinetic parameter of efgartigimod: serum concentration observed predose (Ctrough).

    Time frame: Up to 60 weeks

  17. Pharmacodynamics markers: total IgG.

    Time frame: Up to 60 weeks

07

Study locations

87 sites
  • Investigator Site 0010045
    Washington D.C., District of Columbia 20007, United States
  • Investigator Site 0010037
    Ocala, Florida 34474, United States
  • Investigator Site 0010042
    Iowa City, Iowa 52242, United States
  • Investigator Site 0010040
    Columbus, Ohio 43210, United States
  • Investigator Site 0430002
    Vienna, Austria
  • Investigator Site 0430003
    Vienna, Austria
  • Investigator Site 0320012
    Brasschaat, Belgium
  • Investigator Site 0320011
    Bruges, Belgium
  • Investigator Site 0320014
    Turnhout, Belgium
  • Investigator Site 0320002
    Yvoir, Belgium
  • Investigator Site 3590001
    Pleven, Bulgaria
  • Investigator Site 3590002
    Sofia, Bulgaria
  • Investigator Site 4200001
    Brno, Czechia
  • Investigator Site 4200008
    Olomouc, Czechia
  • Investigator Site 4200006
    Ostrava, Czechia
  • Investigator Site 4200007
    Prague, Czechia
  • Investigator Site 0330009
    Créteil, France
  • Investigator Site 0330018
    Montpellier, France
  • Investigator Site 0330008
    Pessac, France
  • Investigator Site 0330016
    Périgueux, France
  • Investigator site 9950007
    Tbilisi, Georgia
  • Investigator site 9950008
    Tbilisi, Georgia
  • Investigator site 9950009
    Tbilisi, Georgia
  • Investigator site 9950011
    Tbilisi, Georgia
  • Investigator site 9950012
    Tbilisi, Georgia
  • Investigator Site 0490010
    Düsseldorf, Germany
  • Investigator Site 0490008
    Essen, Germany
  • Investigator Site 0360004
    Budapest, Hungary
  • Investigator Site 0360006
    Debrecen, Hungary
  • Investigator Site 0360015
    Győr, Hungary
  • Investigator Site 0360010
    Nyíregyháza, Hungary
  • Investigator Site 0360014
    Szombathely, Hungary
  • Investigator Site 0390014
    Milan, Italy
  • Investigator Site 0390020
    Monza, Italy
  • Investigator Site 0390015
    Novara, Italy
  • Investigator Site 0390010
    Ravenna, Italy
  • Investigator Site 0390011
    Reggio Calabria, Italy
  • Investigator Site 0390018
    Reggio Emilia, Italy
  • Investigator Site 0390019
    Rimini, Italy
  • Investigator Site 0390009
    Siena, Italy
  • Investigator Site 0390016
    Trieste, Italy
  • Investigator Site 0810015
    Hirakata, Japan
  • Investigator Site 0810010
    Hiroshima, Japan
  • Investigator Site 0810017
    Iruma, Japan
  • Investigator Site 0810022
    Kashiwa, Japan
  • Investigator Site 0810018
    Maebashi, Japan
  • Investigator Site 0810021
    Niigata, Japan
  • Investigator Site 0810014
    Sapporo, Japan
  • Investigator Site 0810016
    Shibukawa, Japan
  • Investigator Site 0810023
    Shimotsuke, Japan
  • Investigator Site 0310005
    Rotterdam, Netherlands
  • Investigator Site 0310006
    The Hague, Netherlands
  • Investigator Site 0480012
    Gdansk, Poland
  • Investigator Site 0480013
    Katowice, Poland
  • Investigator Site 0480011
    Lodz, Poland
  • Investigator Site 0480014
    Lublin, Poland
  • Investigator Site 0480026
    Nowy Sącz, Poland
  • Investigator Site 0070006
    Kaluga, Russia
  • Investigator Site 0070008
    Moscow, Russia
  • Investigator Site 0070007
    Petrozavodsk, Russia
  • Investigator Site 0070013
    Rostov-on-Don, Russia
  • Investigator Site 0070015
    Syktyvkar, Russia
  • Investigator Site 0070012
    Tula, Russia
  • Investigator Site 0070010
    Ufa, Russia
  • Investigator Site 0340006
    Barcelona, Spain
  • Investigator Site 0340007
    Barcelona, Spain
  • Investigator Site 0340009
    Madrid, Spain
  • Investigator Site 0340014
    Madrid, Spain
  • Investigator Site 0340012
    Palma de Mallorca, Spain
  • Investigator Site 0340015
    Pozuelo de Alarcón, Spain
  • Investigator Site 0340013
    Seville, Spain
  • Investigator Site 0340004
    Valencia, Spain
  • Investigator Site 0340011
    Valencia, Spain
  • Investigator Site 0900003
    Ankara, Turkey (Türkiye)
  • Investigator Site 0900006
    Ankara, Turkey (Türkiye)
  • Investigator Site 0900015
    Ankara, Turkey (Türkiye)
  • Investigator Site 0900016
    Edirne, Turkey (Türkiye)
  • Investigator Site 0900013
    Istanbul, Turkey (Türkiye)
  • Investigator Site 0900004
    Izmir, Turkey (Türkiye)
  • Investigator Site 0900010
    Mersin, Turkey (Türkiye)
  • Investigator Site 0900007
    Sakarya, Turkey (Türkiye)
  • Investigator Site 0900009
    Samsun, Turkey (Türkiye)
  • Investigator Site 0900017
    Tekirdağ, Turkey (Türkiye)
  • Investigator Site 0900019
    Trabzon, Turkey (Türkiye)
  • Investigator Site 3800006
    Mykolaiv, Ukraine
  • Investigator Site 0440008
    London, United Kingdom
  • Investigator Site 0440012
    Southampton, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Mar 2026, 69 months.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 69 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2020
First posted
Jan 13, 2020
StartActual
Jun 2, 2020
Primary completionActual
Mar 11, 2026
CompletionActual
Mar 11, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04225156
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Jun 2, 2020
Primary completion
Mar 11, 2026
Completion
Mar 11, 2026
Last update
Mar 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion